Trade Mark Journal No.2026/038 18 September 2026
WO0000001936098 (5)
Office of origin: United States of America
Date of International Registration:12 May 2026
Date of designation in the UK:
12 May 2026
International priority date claimed: 12 December 2025
(United States of America)
(99545865)
- Class 5
- Pharmaceutical preparations consisting of monospecific, bispecific, or multi-specific antibody based molecules for the treatment of human diseases, namely, autoimmune, inflammatory, oncologic and neoplastic, infectious, cardiovascular, metabolic, endocrine, respiratory, musculoskeletal, neuromuscular, neurologic, mental health, dermatologic, ophthalmologic, hematologic, renal, gastrointestinal and digestive system, urogenital, reproductive, pediatric and developmental, neurodevelopmental, genetic, rare, namely, chronic, progressive, and life-threatening, and orphan diseases and disorders, conditions related to transplantation and tolerance, and immune mediated conditions; pharmaceutical agents consisting of monospecific, bispecific, or multi-specific antibody based molecules for the treatment of human diseases, namely, autoimmune, inflammatory, oncologic and neoplastic, infectious, cardiovascular, metabolic, endocrine, respiratory, musculoskeletal, neuromuscular, neurologic, mental health, dermatologic, ophthalmologic, hematologic, renal, gastrointestinal and digestive system, urogenital, reproductive, pediatric and developmental, neurodevelopmental, genetic, rare, namely, chronic, progressive, and life-threatening, and orphan diseases and disorders, conditions related to transplantation and tolerance, and immune mediated conditions.
Hinge Bio, Inc.
Representative: Beth M. Goldman Orrick, Herrington & Sutcliffe LLP, 2050 Main Street, Suite 1100,, IP Prosecution Department, Irvine CA 92614-8255, UNITED STATES OF AMERICA